Will Eliquis join Pradaxa and Xarelto as another anti-coagulant drug facing claims of severe internal bleeding? Pradaxa was the first of these three new anti-coagulants (blood thinners). It hit the market in 2010. Sales quickly boomed. However, adverse reports of severe internal hemorrhaging and bleeding soon followed. In May 2014, Pradaxa’s manufacturer settled about 4,000 cases involving patients who suffered tremendous bleeding issues from that dangerous and defective drug.

Xarelto was next. As I wrote in May of this year, investigative journalists have raised serious questions as to whether the clinical trials used to obtain FDA approval for Xarelto were tainted by misconduct. These issues cast serious doubt over the drug. Severe personal injuries associated with Xarelto include:

  • Death due Uncontrolled Bleeding
  • Hemorrhaging
  • Stroke
  • Gastrointestinal Bleeding

In 2012, Pfizer and Bristol-Myers Squibb introduced the newest drug in the class, Eliquis. Despite being a recent drug, Eliquis already faces growing concerns over adverse and uncontrollable bleeding risks. The risk of bleeding is especially troubling with these three anti-coagulants since the drugs lack an effective antidote. An Eliquis patient in Alabama recently filed suit after suffering an intracranial hemorrhage. That case also alleges the clinical trials for Eliquis were tainted by misconduct.

We have continued to follow the research carefully on both Xarelto and Eliquis. The potential harm of these drugs raises serious issues. Patients deserve safe drugs approved only after careful study and accurate clinical trials.